Indication

Postessential Thrombocythemia (Post-ET) Myelofibrosis

1 clinical trial

1 product

Clinical trial

A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)

Status: Completed, Estimated PCD: 2017-07-18

Product